Brief

Here is a summary of the provided document in a few sentences:

The Federal Trade Commission (FTC) enforces federal competition and consumer protection laws to prevent anticompetitive, deceptive, and unfair business practices. The FTC has ordered "Pharma Bro"" Martin Shkreli to face a lifetime ban from the pharmaceutical industry and fined him $64.6 million for his role in orchestrating an illegal anticompetitive scheme to perpetuate a monopoly for the life-saving drug Daraprim. This scheme prevented generic competition and allowed the company to increase the price of the drug from $17.50 per tablet to $750 per tablet.

Summary:
The Federal Trade Commission (FTC) has taken action against Martin Shkreli

Enforcement

We enforce federal competition and consumer protection laws that prevent anticompetitive, deceptive, and unfair business practices.

View Enforcement

,

Search or browse
the Legal Library

Find legal resources and guidance to understand your business responsibilities and comply with the law.

Browse legal resources

,

Take action

,

Competition Matters

,

John Newman & Amy Ritchie, Bureau of Competition

,

,

Policy

We work to advance government policies that protect consumers and promote competition.

View Policy

,

Search or browse
the Legal Library

Find legal resources and guidance to understand your business responsibilities and comply with the law.

Browse legal resources

,

Take action

,

Technology Blog

,

The Office of Technology

,

,

Advice and Guidance

Learn more about your rights as a consumer and how to spot and avoid scams. Find the resources you need to understand how consumer protection law impacts your business.

,

Take action

,

Consumer Advice

,

Business Guidance

,

Servicemembers:
Your tool for financial readiness

Visit militaryconsumer.gov

,

Get consumer protection basics, plain and simple

Visit consumer.gov

,

Learn how the FTC protects free enterprise and consumers

Visit Competition Counts

,

Looking for competition guidance?

Competition Guidance

,

News and Events

,

,


,

Sign up for the latest news

Follow us on social media

         

,

About the FTC

Our mission is protecting consumers and competition by preventing anticompetitive, deceptive, and unfair business practices through law enforcement, advocacy, and education without unduly burdening legitimate business activity.

Learn more about the FTC

,

Looking for legal documents or records? Search the Legal Library instead.

,

Looking for legal documents or records? Search the Legal Library instead.

,

For Release

,

,

Today, the United States Court of Appeals for the Second Circuit affirmed a district court ruling which ordered “Pharma Bro” Martin Shkreli to face a lifetime ban from participating in the pharmaceutical industry and found Shkreli liable for $64.6 million in disgorgement for his role in orchestrating an illegal anticompetitive scheme.

Bureau of Competition Director Henry Liu issued the following statement on the Second Circuit’s order:

“The Second Circuit’s decision is a win for consumers seeking affordable, lifesaving medication and clearly demonstrates that corporate executives will be held personally liable for anticompetitive actions that they help orchestrate. I want to congratulate FTC staff for their hard work on this case and I want to thank our state attorneys general partners for their dedication to this important matter.”

In January 2022, the U.S. District Court for the Southern District of New York held that Shkreli organized an illegal anticompetitive scheme to perpetuate a monopoly for the life-saving drug Daraprim, the gold-standard treatment for a rare, potentially fatal parasitic infection known as toxoplasmosis. The Court imposed a lifetime ban against Shkreli participating in the pharmaceutical industry and found Shkreli liable for $64.6 million in disgorgement. The FTC and state enforcers initiated the case in January 2020 against Shkreli, another individual executive, and the companies they founded, Vyera Pharmaceuticals, LLC, and Phoenixus AG. The U.S. District Court found that the defendants’ anticompetitive scheme prevented generic competition and allowed them to protect their Daraprim price increase from $17.50 per tablet to $750 per tablet.

,

The Federal Trade Commission works to promote competition, and protect and educate consumers. You can learn more about how competition benefits consumers or file an antitrust complaint.  For the latest news and resources, follow the FTC on social mediasubscribe to press releases and read our blog.

,

Office of Public Affairs

,

415-848-5121

Highlights content goes here...

a pharmaceutical executive

Federal Trade Commission

Quick Insight
RADA.AI
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Enter your registered username/email id.

Enter your Email

Enter your email id below to signup.

Enter your Email

Enter your email id below to signup.
Individual Plan
$125 / month OR $1250 / year
Features
Best for: Researchers, Legal professionals, Academics
Enterprise Plan
Contact for Pricing
Features
Best for: Law Firms, Corporations, Government Bodies